Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Myriad Genetics, Inc. - Common Stock
(NQ:
MYGN
)
6.290
UNCHANGED
Delayed Quote
Updated: 4:00 PM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Myriad Genetics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Myriad Genetics’s Q3 2026 earnings call: our top 5 analyst questions
Today 1:01 EST
Myriad Genetics' third quarter was marked by the company's decision to divest its prenatal health business and continued efforts to address reimbursement pre...
Via
StockStory
Topics
Earnings
Myriad Genetics (MYGN) Q3 2026 Earnings Call Transcript
↗
November 05, 2026
Myriad is selling its Prenatal Health unit to Labcorp for $210 million in cash.
Via
The Motley Fool
Topics
Earnings
Myriad Genetics (MYGN) shares skyrocket, what you need to know
November 05, 2026
What happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 8.1% in the morning session after the company reported third-quarter 20...
Via
StockStory
Myriad Genetics (NASDAQ:MYGN) Q3 Beats Estimates, Raises Guidance, and Strikes Prenatal Sale to Labcorp
↗
November 04, 2026
Via
Chartmill
Myriad Genetics Q3 Earnings Call Highlights
↗
November 04, 2026
Myriad Genetics (NASDAQ:MYGN) reported third-quarter revenue of $202.7 million, down 1% from a year earlier, as growth in cancer and mental health testing was offset by a decline in its prenatal...
Via
MarketBeat
Topics
Earnings
Myriad Genetics (NASDAQ:MYGN) reports upbeat Q3 2026, stock jumps 10.7%
November 04, 2026
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported Q3 2026 results beating Wall Street’s revenue expectations, but revenue fell by 1.5% year on y...
Via
StockStory
Earnings to watch: Myriad Genetics (MYGN) reports Q3 results tomorrow
November 02, 2026
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be announcing earnings results this Wednesday afternoon. Here’s what to expect. Myriad Genetics mi...
Via
StockStory
2 Russell 2000 stocks on our watchlist and 1 we ignore
October 29, 2026
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Via
StockStory
Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner
October 21, 2026
Check out the companies making headlines yesterday: Washington Trust Bancorp (NASDAQ:WASH): Regional bank Washington Trust Bancorp (NASDAQ:WASH) rose by 5% o...
Via
StockStory
Top US Stock Movers: Today's Session Gainers and Losers
↗
October 20, 2026
Via
Chartmill
Top Movers: Gainers Rise 55.88%, Losers Fall 53.13% in Today's Session
↗
October 20, 2026
Via
Chartmill
Gap Stocks: Gap-Up and Gap-Down Movers in Today's Session
↗
October 20, 2026
Via
Chartmill
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
October 20, 2026
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 22.2% in the pre-market session after the company agreed to sell its Pr...
Via
StockStory
Topics
Artificial Intelligence
2 Small-Cap Stocks to Consider Right Now and 1 We Turn Down
October 19, 2026
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Via
StockStory
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
October 16, 2026
What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields r...
Via
StockStory
Topics
Bonds
Economy
Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
October 14, 2026
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and...
Via
StockStory
Topics
Artificial Intelligence
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
October 07, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD)...
Via
StockStory
Topics
Artificial Intelligence
Why Is Myriad Genetics (MYGN) Stock Soaring Today
October 02, 2026
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5% in the afternoon session after Craig-Hallum analyst John Wilkin rais...
Via
StockStory
1 Volatile Stock on Our Buy List and 2 We Question
October 02, 2026
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be...
Via
StockStory
3 Reasons MYGN is Risky and 1 Stock to Buy Instead
September 24, 2026
Over the past six months, Myriad Genetics’s stock price fell to $4.01. Shareholders have lost 13% of their capital, which is disappointing considering the S&...
Via
StockStory
Topics
Bankruptcy
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
September 21, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe...
Via
StockStory
Topics
Artificial Intelligence
1 Unpopular Stock That Deserves Some Love and 2 We Turn Down
September 17, 2026
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Via
StockStory
2 Unprofitable Stocks to Research Further and 1 We Find Risky
September 15, 2026
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Via
StockStory
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
September 09, 2026
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...
Via
StockStory
Topics
Artificial Intelligence
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
September 07, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th...
Via
StockStory
Topics
Artificial Intelligence
Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter
September 02, 2026
Check out the companies making headlines yesterday: Myriad Genetics (NASDAQ:MYGN): Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell by 6.2% on Tues...
Via
StockStory
Topics
Economy
Why Myriad Genetics (MYGN) Stock Is Down Today
September 01, 2026
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 6.2% in the afternoon session after Piper Sandler double-downgraded the s...
Via
StockStory
Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks
August 27, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Moderna (NASDAQ:MRNA) and its peers. Over the next f...
Via
StockStory
Topics
Artificial Intelligence
Myriad Genetics and Moderna Shares Plummet, What You Need To Know
August 24, 2026
What Happened? A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders continued to secure prof...
Via
StockStory
1 Small-Cap Stock with Promising Prospects and 2 That Underwhelm
August 18, 2026
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
Via
StockStory
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
